Factors associated with aspiring resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery

Neurosurgery

Volumn 64, Issue 5, 2009, Pages 890-895

  Reavey Cantwell, John F ^a   Fox, W Christopher ^a   Reichwage, Brett D ^a   Fautheree, Gregory L ^a   Velat, Gregory J ^a   Whiting, Jobyna H ^a   Chi, Yueh Yun ^a   Hoh, Brian L ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antiplatelet; Aspirin; Aspirin resistance; Clopidogrel; Endovascular; Platelet assay

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ADULT; ANEURYSM; ANGIOPLASTY; BODY MASS; CLINICAL EVALUATION; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOVASCULAR SURGERY; FEMALE; GROUPS BY AGE; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROSURGERY; PATIENT IDENTIFICATION; PERIPHERAL VASCULAR DISEASE; PREMEDICATION; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; STENOSIS; STENT; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; AGED; ARTICLE; CEREBRAL REVASCULARIZATION; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; ANEURYSM; ASPIRIN; CEREBRAL REVASCULARIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; TICLOPIDINE;

EID: 67650763425     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000341904.39691.2F     Document Type: Conference Paper

References (47)

1. Angiolillo DJ, Fernandez- Ortiz A, Bernardo E, Ramirez C, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Macaya C: Influence of aspirin resistance on platelet function profiles in patients on long- term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 97:38-43, 2006.
2. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy- I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106, 1994.
3. Antithrombotic Trialists' Collaboration: Collaborative meta- analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002.
4. Bauriedel G, Skowasch D, Schneider M, Andrié R, Jabs A, Lüderitz B: Antiplatelet effects of angiotensin- converting enzyme inhibitors compared with aspirin and clopidogrel: A pilot study with whole- blood aggregometry. Am Heart J 145:343-348, 2003.
5. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 103:363-368, 2001.
6. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S: Antiplatelet therapy and platelet function testing. Clin Cardiol 31:I36, 2008.
7. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S: Assessing the current role of platelet function testing. Clin Cardiol 31:I10-I16, 2008.
8. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S: Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol 31:I21-I27, 2008.
9. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339, 1996.
10. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, Lau CP: Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 120:631-635, 2007.
11. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo- controlled trial. Lancet 366:1607-1621, 2005.
12. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non- urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43:1122-1126, 2004.
13. Cheng X, Chen WH, Simon DI: Aspirin resistance or variable response or both? Am J Cardiol 98:11N-17N, 2006.
14. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin- resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650-1655, 2002.
15. Favaloro EJ: Clinical application of the PFA-100. Curr Opin Hematol 9:407-415, 2002.
16. Fitzgerald DJ, Maree A: Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program 2007:114-120, 2007.
17. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B: Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110:1392-1397, 2004.
18. Golanski J, Pluta J, Baraniak J, Watala C: Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists - In vitro experience. Clin Chem Lab Med 42:25-29, 2004.
19. Grotemeyer KH: Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63:587-593, 1991.
20. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two- year follow- up of aspirin responder and aspirin non responder. A pilot- study including 180 post-stroke patients. Thromb Res 71:397-403, 1993.
21. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H: Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250:63-66, 2003.
22. Guerra- Cuesta JI, Montón M, Rodríguez- Feo JA, Jiménez AM, González-Fernández F, Rico LA, García R, Gómez J, Farré J, Casado S, López- Farré A: Effect of losartan on human platelet activation. J Hypertens 17:447-452, 1999.
23. Gum PA, Kottke- Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235, 2001.
24. Gum PA, Kottke- Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961-965, 2003.
25. Gurbel PA, Tantry US: Aspirin and clopidogrel resistance: Consideration and management. J Interv Cardiol 19:439-448, 2006.
26. Hirsh J, Bhatt DL: Comparative benefits of clopidogrel and aspirin in high-risk patient populations: Lessons from the CAPRIE and CURE studies. Arch Intern Med 164:2106-2110, 2004.
27. ISIS-2 Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocar-dial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2:349-360, 1988.
28. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T: Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 40:521-527, 2002.
29. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance. J Am Coll Cardiol 47:27-33, 2006.
30. Lev EI, Ramchandani M, Garg R, Wojciechowski Z, Builes A, Vaduganathan M, Tripathy U, Kleiman NS: Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery. J Thromb Thrombolysis 24:15-21, 2007.
31. Malinin AI, Ong S, Makarov LM, Petukhova EY, Serebruany VL: Platelet inhibition beyond conventional antiplatelet agents: Expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract 60:993-1002, 2006.
32. Marcucci R, Paniccia R, Antonucci E, Gori AM, Fedi S, Giglioli C, Valente S, Prisco D, Abbate R, Gensini GF: Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one- year major adverse coronary events. Am J Cardiol 98:1156-1159, 2006.
33. Maree AO, Fitzgerald DJ: Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 115:2196-2207, 2007.
34. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB: Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567-570, 2006.
35. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators: Effects of pretreatment with clopidogrel and aspirin followed by long- term therapy in patients undergoing percutaneous coronary intervention: The PCI- CURE study. Lancet 358:527-533, 2001.
36. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppen -steiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E: Variable platelet response to low- dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78:1003-1007, 1997.
37. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y: Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin- treated patients. J Thromb Haemost 4:1271-1278, 2006.
38. Poston RS, Gu J, Brown JM, Gammie JS, White C, Nie L, Pierson RN 3rd, Griffith BP: Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 131:122-130, 2006.
39. Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK: Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 29:281-285, 2008.
40. Rocca B, Patrono C: Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 3:1597-1602, 2005.
41. Sabatine MS, Cannon CP, Gibson CM, Lopez- Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST- segment elevation. N Engl J Med 352:1179-1189, 2005.
42. Serebruany VL, Malinin AI, Lowry DR, Sane DC, Webb RL, Gottlieb SO, O'Connor CM, Hennekens CH: Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: A possible additional mechanism for clinical benefits. J Cardiovasc Pharmacol 43:677-684, 2004.
43. Serebruany VL, Pokov AN, Malinin AI, O'Connor C, Bhatt DL, Tanguay JF, Sane DC, Hennekens CH: Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J 151:92-99, 2006.
44. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 288:2411-2420, 2002.
45. Wang TH, Bhatt DL, Topol EJ: Aspirin and clopidogrel resistance: An emerging clinical entity. Eur Heart J 27:647-654, 2006.
46. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, Drzewoski J: Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) - Its relation to metabolic control. Thromb Res 113:101-113, 2004.
47. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502, 2001.